Evidence map›Paper›PMID 37921538›Full record

ArticleJournal of the Royal Society of Medicine2024

Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study.

Ruby Sm Tsang, Utkarsh Agrawal, Mark Joy, Rachel Byford, Chris Robertson, Sneha N Anand, William Hinton, Nikhil Mayor, Debasish Kar, John Williams and 12 more

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Royal Society of Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Why are medicine's leaders missing in action?Journal of the Royal Society of Medicine · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 1 country.

Ruby Sm TsangNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.
Utkarsh AgrawalNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.ORCID 0000-0001-5181-6120
Mark JoyNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.
Rachel ByfordNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.
Chris RobertsonDepartment of Mathematics and Statistics, University of Strathclyde, Glasgow, G1 1XH, UK.
Sneha N AnandNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.
William HintonNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.
Nikhil MayorRoyal Surrey NHS Foundation Trust, Guildford, GU2 7XX, UK.ORCID 0000-0003-2681-2501
Debasish KarNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.
John WilliamsNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.
William VictorRoyal College of General Practitioners, London, NW1 2FB, UK.
Ashley AkbariPopulation Data Science, Swansea University Medical School, Swansea University, Swansea, SA2 8QA, UK.ORCID 0000-0003-0814-0801
Declan T BradleyCentre for Public Health, Queen's University Belfast, Belfast, BT12 6BA, UK.
Siobhan MurphyCentre for Public Health, Queen's University Belfast, Belfast, BT12 6BA, UK.
Dermot O'ReillyCentre for Public Health, Queen's University Belfast, Belfast, BT12 6BA, UK.
Rhiannon K OwenPopulation Data Science, Swansea University Medical School, Swansea University, Swansea, SA2 8QA, UK.
Antony ChuterBREATHE - The Health Data Research Hub for Respiratory Health, Edinburgh, EH16 4SS, UK.
Jillian BeggsBREATHE - The Health Data Research Hub for Respiratory Health, Edinburgh, EH16 4SS, UK.
Gary HowsamRoyal College of General Practitioners, London, NW1 2FB, UK.ORCID 0000-0001-6699-5504
Aziz SheikhUsher Institute, University of Edinburgh, Edinburgh, EH16 4SS, UK.
F D Richard HobbsNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.
Simon de LusignanNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.
University of Oxford · GBQueen's University Belfast · GBRoyal College of General Practitioners · GBSwansea University · GBUniversity of Strathclyde · GBRoyal Surrey NHS Foundation Trust · GBUniversity of Edinburgh · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo estimate the incidence of adverse events of interest (AEIs) after receiving their first and second doses of coronavirus disease 2019 (COVID-19) vaccinations, and to report the safety profile differences between the different COVID-19 vaccines.

designWe used a self-controlled case series design to estimate the relative incidence (RI) of AEIs reported to the Oxford-Royal College of General Practitioners national sentinel network. We compared the AEIs that occurred seven days before and after receiving the COVID-19 vaccinations to background levels between 1 October 2020 and 12 September 2021.

settingEngland, UK.

participantsIndividuals experiencing AEIs after receiving first and second doses of COVID-19 vaccines.

main outcome measuresAEIs determined based on events reported in clinical trials and in primary care during post-license surveillance.

resultsA total of 7,952,861 individuals were vaccinated with COVID-19 vaccines within the study period. Among them, 781,200 individuals (9.82%) presented to general practice with 1,482,273 AEIs. Within the first seven days post-vaccination, 4.85% of all the AEIs were reported. There was a 3-7% decrease in the overall RI of AEIs in the seven days after receiving both doses of Pfizer-BioNTech BNT162b2 (RI = 0.93; 95% CI: 0.91-0.94) and 0.96; 95% CI: 0.94-0.98), respectively) and Oxford-AstraZeneca ChAdOx1 (RI = 0.97; 95% CI: 0.95-0.98) for both doses), but a 20% increase after receiving the first dose of Moderna mRNA-1273 (RI = 1.20; 95% CI: 1.00-1.44)).

conclusionsCOVID-19 vaccines are associated with a small decrease in the incidence of medically attended AEIs. Sentinel networks could routinely report common AEI rates, which could contribute to reporting vaccine safety.

Indexed as

Epidemiologypublic healthvaccination programmes

Identifiers

PMID37921538
PMCPMC11100448
OpenAlexW4388302886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.